FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2288565689> ?p ?o ?g. }

• W2288565689 endingPage "3790" @default.
• W2288565689 startingPage "3782" @default.
• W2288565689 abstract "Abstract Purpose: EGFR is a well-validated target for patients with non–small cell lung cancer (NSCLC). CIMAvax-EGF is a therapeutic cancer vaccine composed of human recombinant EGF conjugated to a carrier protein and Montanide ISA51 as adjuvant. The vaccine is intended to induce antibodies against self EGFs that block EGF–EGFR interaction. Experimental Design: To evaluate overall survival, safety, immunogenicity, and EGF concentration in serum after CIMAvax-EGF, a randomized phase III trial was done in patients with advanced NSCLC. Four to 6 weeks after first-line chemotherapy, 405 patients with stage IIIB/IV NSCLC were randomly assigned to a vaccine group, which received CIMAvax-EGF or a control group, treated with best supportive care. Results: Long-term vaccination was very safe. Most frequent adverse reactions were grade 1 or 2 injection-site pain, fever, vomiting, and headache. Vaccination induced anti-EGF antibodies and decreased serum EGF concentration. In the safety population, median survival time (MST) was 10.83 months in the vaccine arm versus 8.86 months in the control arm. These differences were not significant according the standard log rank (HR, 0.82; P = 0.100), but according a weighted log rank (P = 0.04) that was applied once the nonproportionality of the HR was verified. Survival benefit was significant (HR, 0.77; P = 0.036) in the per-protocol setting (patients receiving at least four vaccine doses): MST was 12.43 months for the vaccine arm versus 9.43 months for the control arm. MST was higher (14.66 months) for vaccinated patients with high EGF concentration at baseline. Conclusions: Switch maintenance with CIMAvax-EGF was well tolerated and significantly increased MST of patients that completed induction vaccination. Baseline EGF concentration predicted survival benefit. Clin Cancer Res; 22(15); 3782–90. ©2016 AACR." @default.
• W2288565689 created "2016-06-24" @default.
• W2288565689 creator A5006318317 @default.
• W2288565689 creator A5008281215 @default.
• W2288565689 creator A5011619590 @default.
• W2288565689 creator A5012475785 @default.
• W2288565689 creator A5016616330 @default.
• W2288565689 creator A5018850710 @default.
• W2288565689 creator A5019910826 @default.
• W2288565689 creator A5022492026 @default.
• W2288565689 creator A5025563729 @default.
• W2288565689 creator A5026932532 @default.
• W2288565689 creator A5027738391 @default.
• W2288565689 creator A5029899178 @default.
• W2288565689 creator A5032973197 @default.
• W2288565689 creator A5035594109 @default.
• W2288565689 creator A5042491150 @default.
• W2288565689 creator A5042963282 @default.
• W2288565689 creator A5056444640 @default.
• W2288565689 creator A5059768682 @default.
• W2288565689 creator A5061553296 @default.
• W2288565689 creator A5065865651 @default.
• W2288565689 creator A5067739096 @default.
• W2288565689 creator A5070339062 @default.
• W2288565689 creator A5070534105 @default.
• W2288565689 creator A5076253948 @default.
• W2288565689 creator A5079606668 @default.
• W2288565689 creator A5080411438 @default.
• W2288565689 creator A5081686302 @default.
• W2288565689 creator A5082123652 @default.
• W2288565689 creator A5082455874 @default.
• W2288565689 creator A5082876928 @default.
• W2288565689 creator A5085936099 @default.
• W2288565689 creator A5087539011 @default.
• W2288565689 creator A5089147165 @default.
• W2288565689 creator A5091661570 @default.
• W2288565689 date "2016-07-31" @default.
• W2288565689 modified "2023-10-17" @default.
• W2288565689 title "A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients" @default.
• W2288565689 cites W1543389126 @default.
• W2288565689 cites W1794730248 @default.
• W2288565689 cites W1967835984 @default.
• W2288565689 cites W1972999648 @default.
• W2288565689 cites W1978880032 @default.
• W2288565689 cites W1982488143 @default.
• W2288565689 cites W1990013637 @default.
• W2288565689 cites W1993615391 @default.
• W2288565689 cites W2011033752 @default.
• W2288565689 cites W2028697741 @default.
• W2288565689 cites W2078331831 @default.
• W2288565689 cites W2099122425 @default.
• W2288565689 cites W2100235578 @default.
• W2288565689 cites W2112621029 @default.
• W2288565689 cites W2128083415 @default.
• W2288565689 cites W2130652363 @default.
• W2288565689 cites W2138297714 @default.
• W2288565689 cites W2138604360 @default.
• W2288565689 cites W2141197908 @default.
• W2288565689 cites W2147996829 @default.
• W2288565689 cites W2155741470 @default.
• W2288565689 cites W2157215695 @default.
• W2288565689 cites W2163983995 @default.
• W2288565689 cites W2171190459 @default.
• W2288565689 cites W2327362588 @default.
• W2288565689 doi "https://doi.org/10.1158/1078-0432.ccr-15-0855" @default.
• W2288565689 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26927662" @default.
• W2288565689 hasPublicationYear "2016" @default.
• W2288565689 type Work @default.
• W2288565689 sameAs 2288565689 @default.
• W2288565689 citedByCount "105" @default.
• W2288565689 countsByYear W22885656892016 @default.
• W2288565689 countsByYear W22885656892017 @default.
• W2288565689 countsByYear W22885656892018 @default.
• W2288565689 countsByYear W22885656892019 @default.
• W2288565689 countsByYear W22885656892020 @default.
• W2288565689 countsByYear W22885656892021 @default.
• W2288565689 countsByYear W22885656892022 @default.
• W2288565689 countsByYear W22885656892023 @default.
• W2288565689 crossrefType "journal-article" @default.
• W2288565689 hasAuthorship W2288565689A5006318317 @default.
• W2288565689 hasAuthorship W2288565689A5008281215 @default.
• W2288565689 hasAuthorship W2288565689A5011619590 @default.
• W2288565689 hasAuthorship W2288565689A5012475785 @default.
• W2288565689 hasAuthorship W2288565689A5016616330 @default.
• W2288565689 hasAuthorship W2288565689A5018850710 @default.
• W2288565689 hasAuthorship W2288565689A5019910826 @default.
• W2288565689 hasAuthorship W2288565689A5022492026 @default.
• W2288565689 hasAuthorship W2288565689A5025563729 @default.
• W2288565689 hasAuthorship W2288565689A5026932532 @default.
• W2288565689 hasAuthorship W2288565689A5027738391 @default.
• W2288565689 hasAuthorship W2288565689A5029899178 @default.
• W2288565689 hasAuthorship W2288565689A5032973197 @default.
• W2288565689 hasAuthorship W2288565689A5035594109 @default.
• W2288565689 hasAuthorship W2288565689A5042491150 @default.
• W2288565689 hasAuthorship W2288565689A5042963282 @default.
• W2288565689 hasAuthorship W2288565689A5056444640 @default.
• W2288565689 hasAuthorship W2288565689A5059768682 @default.
• W2288565689 hasAuthorship W2288565689A5061553296 @default.

• next